Dovitinib synergizes with oxaliplatin in suppressing cell proliferation and inducing apoptosis in colorectal cancer cells regardless of RAS-RAF mutation status

Table 1 Mutation status and IC50(μM) for Dovitinib and Oxaliplatin in Colon cancer cell lines

Cell Lines	HCT-116	HT-29	SW-480	CaCO2	LS174T
*Status*
Drugs
KRAS	M(Gly13Asp)	WT	M(Gly12Val)	WT	M(Gly12Asp)
BRAF	WT	M(Val600Glu)	WT	M(Val600Glu)	WT
PIK3CA/pTEN	M	WT	WT	WT	M
p53	WT	M (273Arg-His)	M (273Arg-His	M	WT
p53	WT	M (273Arg-His)	309Pro-ser)	M	WT
LOH/MSI	MSI	MSS/LOH	MSS/LOH	MSS	MSI
APC	WT	M	M	M	WT
Dovitinib	3.050.58	5.21.93	4.330.47	3.230.64	4.330.47
Oxaliplatin	1.670.17	8.02.0	6.02.08	2.70.15	2.871.27

Abbreviations: M Mutant, WT Wild type, LOH Loss of heterozygosity, MSI Microsatellite instability, MSS Microsatellite stable.

ISSN: 1476-4598